1. Home
  2. MVO vs LIXT Comparison

MVO vs LIXT Comparison

Compare MVO & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MVO

MV Oil Trust Units of Beneficial Interests

HOLD

Current Price

$2.89

Market Cap

26.3M

Sector

Energy

ML Signal

HOLD

Logo Lixte Biotechnology Holdings Inc.

LIXT

Lixte Biotechnology Holdings Inc.

N/A

Current Price

$2.90

Market Cap

26.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MVO
LIXT
Founded
2006
2005
Country
United States
United States
Employees
N/A
3
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.3M
26.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
MVO
LIXT
Price
$2.89
$2.90
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
326.5K
44.5K
Earning Date
01-01-0001
05-11-2026
Dividend Yield
17.46%
N/A
EPS Growth
N/A
N/A
EPS
1.46
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$2.21
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.97
$0.64
52 Week High
$6.40
$6.09

Technical Indicators

Market Signals
Indicator
MVO
LIXT
Relative Strength Index (RSI) 58.75 53.46
Support Level $1.11 $2.97
Resistance Level $3.37 $3.30
Average True Range (ATR) 0.28 0.26
MACD 0.06 0.01
Stochastic Oscillator 59.10 73.65

Price Performance

Historical Comparison
MVO
LIXT

About MVO MV Oil Trust Units of Beneficial Interests

MV Oil Trust is a statutory trust. The trust was created to acquire and hold the net profits interest for the benefit of the Trust unitholders.

About LIXT Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

Share on Social Networks: